ChromaDex Corporation
US ˙ NasdaqCM ˙ US1710774076
TEN SYMBOL NIE JEST JUŻ AKTYWNY

SecurityCDXC / ChromaDex Corporation
InstitutionMillennium Management Llc
ManagerIsrael Englander
Latest Disclosed Ownership551,349 shares
Latest Disclosed Value $ 2,431,449
Millennium Management Llc reports 1.74% decrease in ownership of CDXC / ChromaDex Corporation

On May 15, 2026 - Millennium Management Llc filed a 13F-HR form disclosing ownership of 551,349 shares of ChromaDex Corporation (US:CDXC) valued at $2,431,449 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 561,110 shares of ChromaDex Corporation. This represents a change in shares of -1.74% during the quarter. The current value of the position is $4,339,117 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NIAGEN BIOSCIENCE COM NEW 171077407 551,349 -9,761 -1.74 2,431 -31.87 0.0010
2026-02-17 2025-12-31 13F NIAGEN BIOSCIENCE COM NEW 171077407 561,110 -213,127 -27.53 3,569 -50.60 0.0015
2025-11-14 2025-09-30 13F NIAGEN BIOSCIENCE COM NEW 171077407 774,237 652,684 536.95 7,224 312.51 0.0031
2025-08-14 2025-06-30 13F NIAGEN BIOSCIENCE COM NEW 171077407 121,553 -479,347 -79.77 1,752 -57.77 0.0008
2025-05-15 2025-03-31 13F NIAGEN BIOSCIENCE COM NEW 171077407 600,900 374,811 165.78 4,146 245.79 0.0022
2025-02-14 2024-12-31 13F CHROMADEX COM NEW 171077407 226,089 226,089 1,199 0.0006
2024-11-14 2024-09-30 13F CHROMADEX COM NEW 171077407 0 -192,341 -100.00 0 -100.00
2024-08-14 2024-06-30 13F CHROMADEX COM NEW 171077407 192,341 -391,941 -67.08 525 -74.18 0.0002
2024-05-15 2024-03-31 13F CHROMADEX COM NEW 171077407 584,282 459,186 367.07 2,033 1,042.13 0.0009
2024-02-14 2023-12-31 13F CHROMADEX COM NEW 171077407 125,096 -105,601 -45.77 179 -47.02 0.0001
2023-11-14 2023-09-30 13F CHROMADEX COM NEW 171077407 230,697 -50,376 -17.92 337 -23.81 0.0002
2023-08-14 2023-06-30 13F CHROMADEX COM NEW 171077407 281,073 -231,839 -45.20 441 -43.82 0.0002
2023-05-15 2023-03-31 13F CHROMADEX COM NEW 171077407 512,912 -149,955 -22.62 785 -29.53 0.0005
2023-02-14 2022-12-31 13F CHROMADEX COM NEW 171077407 662,867 462,204 230.34 1,114 351.01 0.0006
2022-11-14 2022-09-30 13F CHROMADEX COM NEW 171077407 200,663 -562,930 -73.72 247 -80.63 0.0001
2022-08-15 2022-06-30 13F CHROMADEX COM NEW 171077407 763,593 763,593 1,275 0.0008
2022-05-16 2022-03-31 13F CHROMADEX COM NEW 171077407 0 -225,920 -100.00 0 -100.00
2022-02-14 2021-12-31 13F CHROMADEX COM NEW 171077407 225,920 72,852 47.59 845 -11.98 0.0004
2021-11-15 2021-09-30 13F CHROMADEX COM NEW 171077407 153,068 50,850 49.75 960 -4.76 0.0006
2021-08-16 2021-06-30 13F CHROMADEX COM NEW 171077407 102,218 -806,695 -88.75 1,008 -88.13 0.0006
2021-05-17 2021-03-31 13F CHROMADEX COM NEW 171077407 908,913 812,958 847.23 8,489 1,741.43 0.0061
2021-02-16 2020-12-31 13F CHROMADEX COM NEW 171077407 95,955 -107,091 -52.74 461 -43.37 0.0003
2020-11-16 2020-09-30 13F CHROMADEX COM NEW 171077407 203,046 103,997 105.00 814 78.90 0.0010
2020-08-14 2020-06-30 13F CHROMADEX COM NEW 171077407 99,049 99,049 455 0.0006
2020-02-14 2019-12-31 13F CHROMADEX COM NEW 171077407 0 -154,733 -100.00 0 -100.00
2019-11-14 2019-09-30 13F CHROMADEX COM NEW 171077407 154,733 133,985 645.77 608 533.33 0.0010
2019-08-15 2019-06-30 13F/A-1 CHROMADEX COM NEW 171077407 20,748 20,748 96 0.0001
2019-08-14 2019-06-30 13F HUNT J B TRANS SVCS COM 171077407 57,403 57,403 5,247
2018-08-14 2018-06-30 13F CHROMADEX COM NEW 171077407 0 -504,525 -100.00 0 -100.00
2018-05-15 2018-03-31 13F CHROMADEX COM NEW 171077407 504,525 -38,469 -7.08 2,119 -33.64 0.0028
2018-02-14 2017-12-31 13F CHROMADEX COM NEW 171077407 542,994 205,852 61.06 3,193 120.21 0.0044
2017-11-14 2017-09-30 13F CHROMADEX COM NEW 171077407 337,142 -22,403 -6.23 1,450 5.61 0.0022
2017-08-14 2017-06-30 13F CHROMADEX COM NEW 171077407 359,545 204,010 131.17 1,373 228.47 0.0024
2017-05-15 2017-03-31 13F CHROMADEX COM NEW 171077407 155,535 -73,547 -32.11 418 -44.85 0.0008
2017-02-14 2016-12-31 13F CHROMADEX COM NEW 171077407 229,082 229,082 758 0.0016
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.